Lipocine Inc (LPCN)

  • Get an in-depth profile of Lipocine Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
4.7400 -0.4700 (-9.02%)
Closed USD Disclaimer
4.9700 +0.2300 (+4.8523%)

Lipocine Inc Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
15
Equity Type
ORD
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging its Lip’ral platform to develop differentiated products through oral delivery. It has a portfolio of differentiated product candidates that target high unmet needs for neurological and psychiatric Central Nervous System (CNS) disorders, liver diseases, and hormone supplementation for men and women. The Company's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its clinical development pipeline candidates include LPCN 1154 for postpartum depression (PPD), LPCN 2101 for epilepsy, and LPCN 1148 an androgen therapy for the management of cirrhosis. The Company is focused on exploring partnering opportunities for LPCN 1107, its candidate for the prevention of preterm birth; LPCN 1148, for the management of decompensated cirrhosis; LPCN 1144, its candidate for the treatment of non-cirrhotic NASH, and LPCN 1111.
Contact Information
Address
Salt Lake City,84108 United States
Phone
801 994 7383
Fax
801 994 7388
Web
https://www.lipocine.com
Top Executives
Name
Age
Since
Title
Jill M. Jene 49 2022 Independent Director
Mahesh V. Patel 65 1997 Co-Founder, Interim Principal Financial Officer, Director, President & CEO
Spyridon Papapetropoulos 49 2022 Lead Director & Chairman of the Board
William N. Charman 63 0000 Member of Scientific Advisory Board
Richard Dana Ono 70 2014 Independent Director
Alan F. Hofmann 0 0000 Member of Scientific Advisory Board
George Zografi 0 0000 Member of Scientific Advisory Board
Leslie Z. Benet 85 0000 Member of Scientific Advisory Board
Tsuneji Nagai 0 0000 Member of Scientific Advisory Board
John W. Higuchi 55 2003 Director
Bradley D. Anderson 0 0000 Member of Scientific Advisory Board
Ronald T. Borchardt 0 0000 Member of Scientific Advisory Board
Norman Ho 0 0000 Member of Scientific Advisory Board
Jeffrey Arvin Fink 65 2014 Independent Director

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.